Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice T Shaw

Showing results (121-130 of 205) with videos related to

Pageof 21
Sort By:
The New England Journal of Medicine|June 7, 2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung CancerSolange Peters, D Ross Camidge, Alice T Shaw, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain MetastasesDaniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2019
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLCMakoto Nishio, Enriqueta Felip, Sergey Orlov, et al.
The Lancet. Oncology|November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trialAlice T Shaw, Benjamin J Solomon, Rita Chiari, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2019
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX StudyD Ross Camidge, Rafal Dziadziuszko, Solange Peters, et al.
Clinical Pharmacokinetics|December 11, 2023
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung CancerJoseph Chen, Alessandra Bearz, Dong-Wan Kim, et al.
The Lancet. Oncology|November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialScott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2018
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung CancerAlexa B Schrock, Allison Welsh, Jon H Chung, et al.
Science Translational Medicine|January 27, 2012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung CancersRyohei Katayama, Alice T Shaw, Tahsin M Khan, et al.
Lung Cancer (Amsterdam, Netherlands)|April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerSolange Peters, Alice T Shaw, Benjamin Besse, et al.
Pageof 21

Showing results (121-130 of 205) with videos related to

Sort By:
Pageof 21
The New England Journal of Medicine|June 7, 2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung CancerSolange Peters, D Ross Camidge, Alice T Shaw, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain MetastasesDaniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2019
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLCMakoto Nishio, Enriqueta Felip, Sergey Orlov, et al.
The Lancet. Oncology|November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trialAlice T Shaw, Benjamin J Solomon, Rita Chiari, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 24, 2019
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX StudyD Ross Camidge, Rafal Dziadziuszko, Solange Peters, et al.
Clinical Pharmacokinetics|December 11, 2023
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung CancerJoseph Chen, Alessandra Bearz, Dong-Wan Kim, et al.
The Lancet. Oncology|November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialScott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2018
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung CancerAlexa B Schrock, Allison Welsh, Jon H Chung, et al.
Science Translational Medicine|January 27, 2012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung CancersRyohei Katayama, Alice T Shaw, Tahsin M Khan, et al.
Lung Cancer (Amsterdam, Netherlands)|April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerSolange Peters, Alice T Shaw, Benjamin Besse, et al.
Pageof 21